CLINDIROS M 25 Tablet Extended Release is a medication indicated for the management of hypertension, commonly known as high blood pressure. This formulation combines two active substances that work together to achieve better control of blood pressure when monotherapy is insufficient. Effective blood pressure regulation is crucial as it can significantly reduce the risk of serious cardiovascular events such as heart attacks and strokes. It is recommended that you take CLINDIROS M 25 Tablet ER consistently at the same time each day, preferably with meals, to enhance its effectiveness. Adherence to your healthcare provider’s recommendations is essential; discontinuing the medication without medical advice may lead to a worsening of your condition, particularly since hypertension frequently presents without noticeable symptoms. Maintaining a balanced lifestyle, which includes regular physical activity, achieving a healthy weight, and following a nutritious diet, can further assist in managing your blood pressure. While undergoing treatment, you may experience side effects including headaches, swelling in the ankles, reduced heart rate, and feelings of nausea. Additionally, dizziness can occur, so it is advised to avoid driving or engaging in tasks that require clear mental acuity until you are familiar with how the medication influences you. Regular monitoring of your blood pressure, kidney function, blood glucose levels, and electrolyte balance may also be necessary during your treatment. Prior to initiating this medication, inform your healthcare provider of any existing liver or kidney issues. It is also important for pregnant or breastfeeding individuals to seek professional guidance before starting this treatment, and to disclose any other medications they are currently taking, particularly those for hypertension or heart conditions.
-47%

CLINDIROS M 25 (Cilnidipine (10mg) + Metoprolol Succinate (25mg))
Original price was: ₹75.80.₹40.00Current price is: ₹40.00.
Add to cart
Buy Now

Reviews
There are no reviews yet.